Key result
Preoperative high-dose atorvastatin is linked to ~34% lower postoperative troponin-I vs low-dose in CABG.
Why the study?
CABG is commonly associated with perioperative myocardial injury reflected by elevated cTn-I levels, and the anti-inflammatory and antioxidant properties of preoperative high-dose atorvastatin may reduce this myocardial damage.
Does preoperative high-dose atorvastatin (80 mg/day for 2 days) reduce postoperative 24-hour cardiac troponin-I levels compared to low-dose atorvastatin (10 mg/day) in patients undergoing conventional on-pump CABG?
Observational (n=60)
No
Does preoperative high-dose atorvastatin (80 mg/day for 2 days) reduce postoperative 24-hour cardiac troponin-I levels compared to low-dose atorvastatin (10 mg/day) in patients undergoing conventional on-pump CABG?
Short-term preoperative loading with high-dose atorvastatin (80 mg/day for 2 days) significantly attenuates early postoperative myocardial injury marker (troponin-I) release compared to low-dose atorvastatin in patients undergoing conventional on-pump CABG.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for myocardial protection with high-dose atorvastatin before CABG; leaves open whether benefits extend to clinical outcomes in randomized trials.
Introduction: Coronary artery bypass grafting (CABG) is commonly associated with perioperative myocardial injury, reflected by elevated cardiac troponin-I (cTn-I) levels. Atorvastatin possesses anti-inflammatory and antioxidant properties that may reduce myocardial damage following CABG. Objectives: To evaluate the effect of preoperative high-dose atorvastatin therapy on myocardial injury in patients undergoing conventional on-pump CABG and to compare postoperative troponin-I levels between high-dose and low-dose atorvastatin groups. Materials and Methods: This prospective observational study was conducted at the National Institute of Cardiovascular Diseases and Hospital, Dhaka, Bangladesh, from January 2011 to December 2012 among 60 patients undergoing conventional CABG. Patients were divided into two groups: Group I (n=30) received atorvastatin 80 mg/day for 2 days preoperatively, while Group II (n=30) received atorvastatin 10 mg/day. Demographic variables, risk factors, cardiopulmonary bypass time, aortic cross-clamp time, and serum troponin-I levels were compared. Troponin-I was measured preoperatively and 24 hours postoperatively. Data were analyzed using SPSS. Results: Baseline demographic characteristics, cardiovascular risk factors, left ventricular ejection fraction, cardiopulmonary bypass time, and aortic cross-clamp time were comparable between the groups (p>0.05). Preoperative troponin-I levels showed no significant difference. However, postoperative 24-hour troponin-I levels were significantly lower in Group I compared with Group II (1.79±0.23 ng/ml vs 2.72±0.24 ng/ml; p<0.0001). Discussion and Conclusion: Preoperative high-dose atorvastatin significantly reduced postoperative myocardial injury marker levels following conventional CABG. High-dose atorvastatin therapy appears safe and may provide myocardial protection in patients undergoing on-pump CABG. Medicine Today 2026, Vol.38 (2): 228-231
No takes yet. Share an insight, caveat, or question.
Alam et al. (2026) conducted an observational in Coronary artery disease undergoing conventional on-pump coronary artery bypass grafting (CABG) (n=60). Preoperative high-dose atorvastatin vs. Low-dose atorvastatin (10 mg/day) was evaluated on Postoperative 24-hour serum cardiac troponin-I (cTn-I) level (ng/ml) (p=<0.0001). Preoperative high-dose atorvastatin (80 mg/day) significantly lowered 24-hour postoperative troponin-I levels compared to 10 mg/day (1.79±0.23 vs 2.72±0.24 ng/ml; p<0.0001) after on-pump CABG.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: